Adam’s Take
Insights and opinions from senior biotech writer Adam Feuerstein
Most Read
STAT Plus: A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy
STAT Plus: A company developing a human blood substitute attempts a comeback, but IPO plans look dicey
STAT Plus: What Regeneron’s purchase of Checkmate Pharma says about the state of biotech
STAT Plus: Cel-Sci’s CEO used private call to tip off select investors about cancer drug update
STAT Plus: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies
STAT Plus: Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
STAT Plus: An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more
All Coverage
advertisement
